Company Description
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States.
The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.
It is also developing OPN-019 that combines liquid EDS device with an antiseptic.
The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation.
OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.
| Country | United States |
| IPO Date | Oct 13, 2017 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 132 |
| CEO | Dr. Ramy A. Mahmoud M.D., M.P.H. |
Contact Details
Address: 1020 Stony Hill Road Yardley, Pennsylvania United States | |
| Website | https://www.optinose.com |
Stock Details
| Ticker Symbol | OPTN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001494650 |
| CUSIP Number | 68404V100 |
| ISIN Number | US68404V1008 |
| Employer ID | 42-1771610 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ramy A. Mahmoud M.D., M.P.H. | Chief Executive Officer & Director |
| Michael F. Marino Esq. | Chief Legal Officer & Corporate Secretary |
| P. Terence Kohler | Chief Financial Officer |
| Anthony J. Krick | Vice President of Finance & Chief Accounting Officer |
| Jonathan Neely | Vice President of Investor Relations & Business Development |
| Karen E. Brophy | Chief Human Resources Officer & Vice President of Human Resources |
| Paul Spence | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 30, 2024 | 8-K | Current Report |
| Dec 23, 2024 | 8-K | Current Report |
| Dec 18, 2024 | 4 | Filing |
| Dec 18, 2024 | 4 | Filing |
| Dec 12, 2024 | DEF 14A | Filing |
| Dec 02, 2024 | PRE 14A | Filing |
| Nov 27, 2024 | DEF 14A | Filing |
| Nov 20, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SCHEDULE 13G | Filing |